Recognizing Potential Diabetes Drug Cancer Risks during Cancer Control Month

April is Cancer Control Month and Anapol Schwartz law firm is reminding diabetes patients about increased cancer risks multiple researchers have linked to diabetes drugs such as Actos, Byetta and Januvia.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Philadelphia, PA (PRWEB) April 01, 2013

April is National Cancer Control Month, and the Anapol Schwartz law firm is reminding diabetes patients about possible increased cancer risks associated with certain diabetes drugs such as Actos, Byetta and Januvia.

“An estimated half a million Americans will lose their lives to cancer, and three times that many will be diagnosed with this devastating illness.” President Barack Obama said last year in a statement declaring April National Cancer Control Month.* It is therefore imperative that diabetes patients be aware of the cancer risks certain medications have been demonstrated to possibly increase, so they can make informed decisions about their personal diabetes treatment.

Patients taking Actos or the generic pioglitazone for more than one year have a 40 percent higher risk of bladder cancer, according to an ongoing study by drug manufacturer Takeda. Actos was banned in France and Germany after an epidemiological study associated Actos and bladder cancer.** The U.S. Food and Drug Administration (FDA) alerted the public in August 2011 that Actos drug labels and safety information for pioglitazone-containing medications have been updated to highlight these known problems.**

The FDA is also currently evaluating unpublished academic research that suggests an increased risk of pre-cancerous cellular changes in diabetes patients using drugs such as Byetta and Januvia to control their blood sugar. The agency has requested the research methodology and tissue samples so they can investigate a potential association between Januvia and Byetta with cancer.*** The Anapol Schwartz law firm is committed to providing the public with up-to-date information about this investigation as it becomes available.

“When people are already dealing with the difficulties associated with diabetes, they shouldn’t have to also suffer from a painful and deadly cancer,” said diabetes drug lawyer Mike Schafle. “Adding the potential increased cancer risks to drug labels is only the first step in the right direction of preventing dangerous drugs from hurting unsuspecting people.”

Patients should never alter or discontinue their current medications or treatment without first consulting their physicians. Diabetes patients who acquired pancreatic cancer after using Januvia or Byetta or bladder cancer after using Actos can contact the national law firm of Anapol Schwartz to discuss their legal rights.

###

Anapol Schwartz is national leader in product liability and pharmaceutical litigation, having successfully litigated thousands of cases in state and federal courts during the last 30 years. The firm has obtained hundreds of millions of dollars in successful verdicts, settlements and judgments on behalf of its clients.

*http://www.whitehouse.gov/the-press-office/2012/04/02/presidential-proclamation-national-cancer-control-month-2012
**http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm226257.htm
***http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm343805.htm


Contact